Home » Emerging technologies » Gene editing » Synthego’s CRISPR Platform Enables Faster Identification of Potential Coronavirus Treatment

Synthego’s CRISPR Platform Enables Faster Identification of Potential Coronavirus Treatment

International Study Published in Science Describes Synthego’s Platform Application to Study Genes Associated with SARS-CoV-2

REDWOOD CITY, Calif.Oct. 15, 2020 /PRNewswire/ — Synthego, the genome engineering company, has collaborated with The Krogan Lab, a world-renowned scientific research unit at the Quantitative Biosciences Institute (QBI) at the University of California, San Francisco (UCSF), to deliver multiple CRISPR-based engineered cell lines to accelerate the study of potential treatment targets for SARS-CoV-2, the novel coronavirus that causes COVID-19 disease. In a study published in Science [https://science.sciencemag.org/content/early/2020/10/14/science.abe9403], the consortium of researchers used Synthego-engineered cells targeting more than 300 genes that the virus interacts with inside a human cell.

“Utilizing Synthego’s industry-leading CRISPR-based genome engineering platform was essential in accelerating our research at QBI’s Coronavirus Research Group,” said Dr. Krogan, a professor at UCSF, Director of QBI, and a senior investigator at the Gladstone Institutes. “The precision and reproducibility of CRISPR were key to helping us study how SARS-CoV-2 affects cellular pathways and ultimately causes disease, enhancing our validation of promising therapeutic targets that may offer broad protection against infection from coronaviruses.”

In this collaboration, Synthego joined academic and private sector scientists from UCSF, QBI’s Coronavirus Research Group (QCRG), Gladstone Institutes, EMBL’s European Bioinformatics Institute (EMBL-EBI) in Cambridge, EnglandGeorgia Institute of Technology, the Icahn School of Medicine at Mount Sinai in New York, Institut Pasteur in ParisUniversity of Freiburg in Germany, and University of Sheffield in the UK.

Inspired by UCSF’s Nature publication, “A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing,” Synthego extended its expertise and platform technologies to validate the targets identified in the study by editing genes individually and as a series. This approach revealed which genes and cellular pathways are essential for the virus to infect and or grow inside human cells through infectivity analysis.

“Contributing to the critical work of an international team of almost 200 researchers from 14 leading institutions in six countries has been a tremendous honor,” said Kevin Holden, a co-author of the study and head of Science at Synthego. “Recent publications, combined with our upcoming World CRISPR Day, highlight our growing scientific expertise and leadership in applying the latest genome engineering platform innovations to advancing life sciences research and clinical development.”

Dr. Krogan will be speaking in greater detail about the Science study and the collaborative effort at Synthego’s upcoming World CRISPR Day symposium, which will also feature a keynote address from Nobel Laureate Jennifer Doudna, Ph.D.

About Synthego
Synthego is a genome engineering company that enables the acceleration of life science research and development in the pursuit of improved human health. The company leverages machine learning, automation, and gene editing to build platforms for science at scale. With its foundations in engineering disciplines, the company’s platforms vertically integrate proprietary hardware, software, bioinformatics, chemistries, and molecular biology to advance life sciences from basic research through therapeutic development programs. By providing commercial and academic researchers, and therapeutic developers with unprecedented access to cutting-edge genome engineering products and services, Synthego is at the forefront of innovation in engineered biology.

SOURCE Synthego



Press Release

Click here to join our weekly newsletter. We want to hear what you think about this article. Got a tip for our news team? Write to editorial@synbiobeta.com.

Add comment

Job opportunities